Surrogate marketing and ethical challenges in infant nutrition
Source:The Hindu ↗
Why It Matters
The issue sits at the critical intersection of GS2 Health Policy and GS4 Ethics. It showcases how corporate surrogate marketing can bypass legislative safeguards like the IMS Act meant to protect infant and maternal health, while also highlighting the profound ethical dilemmas in medical practice regarding corporate sponsorships.
Summary
Paediatricians and public health experts convened in Chennai for the 'Clinical Updates in Indian Breastfeeding Practice' to discuss ethical guidelines surrounding breastfeeding. A central issue raised was the prevalent use of surrogate marketing by baby milk formula brands. Despite the stringent provisions of the Infant Milk Substitutes (IMS) Act, 1992—which prohibits direct promotion of infant milk substitutes and bans brands from sponsoring healthcare professionals—companies are increasingly exploiting loopholes. They market 'prebiotics' for toddler digestion and sponsor 'mom influencers' on social media platforms to subtly promote formula. Experts from the Breastfeeding Promotion Network of India (BPNI) highlighted the ethical conflicts faced by medical professionals targeted by these brands and emphasized the need to rigorously uphold public health policies that promote exclusive breastfeeding.
Key Points
- Health practitioners and public health experts discussed ethical breastfeeding guidelines at the 'Clinical Updates in Indian Breastfeeding Practice' event in Chennai.
- The Infant Milk Substitutes (IMS) Act, 1992 prohibits direct marketing of infant milk substitutes and bans baby food brands from sponsoring health professionals.
- Baby milk formula brands are increasingly employing surrogate marketing tactics, such as promoting 'prebiotics' for digestion rather than explicitly advertising formula milk.
- Companies are exploiting social media by using 'mom influencers' and Instagram reels to subtly influence mothers and bypass traditional advertising regulations.
- Experts emphasized the necessity of strict enforcement of the IMS Act and highlighted the ethical responsibility of pediatricians to resist corporate sponsorships that undermine breastfeeding promotion.
Important Terms
Infant Milk Substitutes (IMS) Act, 1992
A 1992 law (amended 2003) regulating marketing of infant milk substitutes, feeding bottles, and foods. It strictly prohibits advertising and formula industry sponsorship of healthcare professionals to protect breastfeeding.
UPSC context
GS Paper II (Health/Governance). Tests knowledge of legal frameworks protecting child nutrition and curbing aggressive commercial marketing.
Breastfeeding Promotion Network of India (BPNI)
An independent national watchdog founded in 1991, notified by the Indian government to monitor compliance with the IMS Act and advocate for exclusive breastfeeding policies.
UPSC context
GS Paper II (NGOs/Civil Society). Relevant for the role of specialized civil society organizations in policy implementation and monitoring.
Surrogate Marketing
An unethical strategy where brands promote restricted products (like formula) by advertising related unrestricted items (like prebiotics) or using indirect channels (like social media influencers) to bypass legal bans.
UPSC context
GS Paper IV (Applied Ethics). Analyzes corporate ethics, regulatory loopholes, and the conflict between profit-driven marketing and public health.
Exclusive Breastfeeding
The practice of feeding an infant only breast milk—excluding water and other liquids—for the first six months of life to ensure optimal growth and immunity.
UPSC context
GS Paper II (Social Justice/Health). Fundamental for understanding maternal-child health metrics and NFHS (National Family Health Survey) indicators.
Conflict of Interest
In medical ethics, a situation where a practitioner's professional judgment regarding patient health (e.g., recommending breastfeeding) is compromised by secondary financial interests or industry sponsorships.
UPSC context
GS Paper IV (Professional Ethics). Tests ability to navigate ethical dilemmas involving the doctor-industry nexus and institutional integrity.
Prelims Trap
"High institutional delivery rates ensure the nearly universal initiation of breastfeeding within one hour of birth."
NFHS-5 data shows a stark paradox: while institutional deliveries are high (88.6%), early initiation of breastfeeding is shockingly low (41.8%), highlighting severe postnatal care gaps.
Static Concepts Connected
What are India's primary regulatory and promotional frameworks for breastfeeding?
- IMS Act 1992: Bans the direct promotion, advertising, and distribution of infant milk substitutes and feeding bottles, and prohibits health worker sponsorships.
- MAA Programme: "Mothers' Absolute Affection" is a flagship MoHFW initiative aiming to build community and health-system support for exclusive breastfeeding for the first six months.
- Role of BPNI: A notified NGO empowered under the IMS Act to officially monitor, document, and report legal violations by baby food corporations.
What is surrogate marketing in the context of corporate ethics?
- Definition: Promoting banned or heavily restricted products under the guise of an unregulated, loosely related product (e.g., selling 'prebiotics' to subtly push formula).
- Ethical Deficit: It deliberately circumvents the spirit of public health legislation, leveraging informational asymmetry to exploit vulnerable demographics like new mothers.
Cross-Topic Patterns
CCPA Influencer Guidelines & Formula Marketing
The Central Consumer Protection Authority (CCPA) requires social media influencers to disclose material connections. Formula brands using 'mom influencers' to bypass the IMS Act links health regulations directly with digital consumer protection.
FSSAI Standards vs. Corporate Interests
Recent controversies over excessive added sugar in commercial baby foods link directly to FSSAI standards, showcasing a recurrent theme of corporate interests undermining optimal infant nutrition.
Expect a GS2/GS4 question linking the paradox of high institutional deliveries in NFHS-5 with corporate ethics bypassing the IMS Act 1992.
Linked PYQs · 4
Linked PYQs · 4
- 2020MainsGS2
In order to enhance the prospects of social development, sound and adequate health care policies are needed particularly in the fields of geriatric and maternal health care. Discuss.
- 2016MainsGS2
Examine the main provisions of the National Child Policy and throw light on the status of its implementation.
- 2024MainsGS4
Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan's team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one's own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation ? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?
- 2024MainsGS4
Sneha is a Senior Manager working for a big reputed hospital chain in a mid-sized city. She has been made in-charge of the new super speciality center that the hospital is building with state-of-the art equipment and world class medical facilities. The building has been reconstructed and she is starting the process of procurement for various equipment and machines. As the head of the committee responsible for procurement, she has invited bids from all the interested reputed vendors dealing in medical equipment. She notices that her brother, who is a well-known supplier in this domain, has also sent his expression of interest. Since the hospital is privately owned, it is not mandatory for her to select only the lower bidder. Also, she is aware that her brother's company has been facing some financial difficulties and a big supply order will help him recover. At the same time, allocating the contract to her brother might bring charges of favouritism against her and tarnish her image. The hospital management trusts her fully and would support any decision of hers. (a) What should be Sneha's course of action? (b) How would she justify what she chooses to do? (c) In this case, how is medical ethics compromised with vested personal interest?
